A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is potentially a curative therapeutic option for hematological malignancies. In clinical practice, transplantation associated complications greatly affected the final therapeutical outcomes. Currently, primary disease relapse, graft-versus-host disease (GVHD) and infections remain the three leading causes of a high morbidity and mortality in allo-HSCT patients. Various strategies have been investigated in the past several decades including human γδ T cell-based therapeutical regimens.
Source: Blood Reviews - Category: Hematology Authors: Tags: REVIEW Source Type: research